A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie
AbbVie
Astellas Pharma Inc
Astellas Pharma Inc
Nanjing Leads Biolabs Co.,Ltd
Eli Lilly and Company
Vividion Therapeutics, Inc.
Ruijin Hospital
AbbVie
AstraZeneca
Tesaro, Inc.
Krystal Biotech, Inc.
Weill Medical College of Cornell University
Genelux Corporation
National University Hospital, Singapore
AbbVie
Trishula Therapeutics, Inc.
NuCana plc
AbbVie
GlaxoSmithKline
Ukrainian Society of Clinical Oncology
Columbia University